In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Evolus (EOLS – Research Report), with a price target of $16.00. The company’s shares closed last Friday at $12.75.
Prasad covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals, Zoetis, and Revance Therapeutics. According to TipRanks, Prasad has an average return of 3.5% and a 44.78% success rate on recommended stocks.
Evolus has an analyst consensus of Strong Buy, with a price target consensus of $23.00, which is an 80.39% upside from current levels. In a report released on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $27.00 price target.
EOLS market cap is currently $798.3M and has a P/E ratio of -12.20.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EOLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus (EOLS) Company Description:
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
